Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • Gilead's Newer Tenofovir Patents

    The company may have found a way to protect its newest HIV franchise for longer than anticipated, perhaps 10 years longer than it suggests in its 10-K (see p. 15), in both the US and EU.

    15 August 2017 | Seeking Alpha
  • A massive second global wave of AIDS is coming — perhaps within the next 10 years

    Three problems are driving the global fight against HIV into a new danger zone. First, new infections increasingly involve forms of the virus that are already resistant to the primary drugs used to treat and prevent HIV infection. Second, the world is fast approaching the limits of manufacturing capacity for anti-HIV first-line drugs, and the ceiling is far lower for second- and third-line treatments. And third, there aren’t sufficient financial resources applied to the AIDS problem now, and signals from major donors — especially the U.S. government — offer a grim future of diminished resources and greater demands on very poor countries to finance their own HIV fights without outside help.

    31 July 2017 | Business Insider
  • WHO prequalifies first generic hepatitis C medicine and first HIV self-test

    WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories Ltd., India.

    22 July 2017 | World Health Organization
  • More people living with HIV in Kyiv accessing antiretroviral therapy

    A public–private partnership between the Elena Pinchuk ANTIAIDS Foundation and the city of Kyiv.

    14 July 2017 | UNAIDS
  • An arbitrary benchmark for access to new drugs

    Policy is an admission the UK cannot afford to be at the cutting edge.

    11 July 2017 | Financial Times
  • Senior MPs urge post-Brexit EU drug regulation deal

    The move would be "in the interests of public health and safety," say Greg Clark and Jeremy Hunt.

    04 July 2017 | BBC Health
  • MSF: HIV response in West and Central Africa will not succeed if key barriers remain unaddressed

    MSF strongly commends the vital leadership shown by UNAIDS and African states in initiating the Acceleration Plan. African leaders are urged to address any limiting factors which may prevent its full realisation. These include legal and policy blockages, centralised health systems, weak procurement and supply chain management, financial barriers, including user fees for patients, and high levels of stigma. MSF also asks for the Acceleration Plan to soon include remaining countries in the region that face similar treatment gaps.

    04 July 2017 | Médecins Sans Frontières (MSF) International
  • Kenya to introduce better treatment for people living with HIV

    To accelerate access to better antiretroviral (ARV) drugs, the Government of Kenya and Unitaid today announced the introduction of dolutegravir, a new first-line drug for people living with HIV, making Kenya the first African country to introduce the generic version of this new drug for routine use.

    28 June 2017 | UNITAID
  • Dolutegavir access in the Asia-Pacific region

    This factsheet provides information on the use of dolutegravir in HIV treatment and access to dolutegravir under Medicines Patent Pool voluntaray licenses.

    27 June 2017 | amfAR Treat Asia
  • FDA Approves Generic Truvada for HIV Treatment and PrEP

    In a move that has taken HIV advocates by surprise and stewed considerable confusion, the U.S. Food and Drug Administration (FDA) has approved a generic formulation of Gilead Sciences’ blockbuster antiretroviral (ARV) Truvada (tenofovir disoproxil fumarate/emtricitabine). This decision could have major implications for the future cost of Truvada, to insurers and consumers alike.

    10 June 2017 | Poz
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.